Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Cancer Survival Analysis01:21

Cancer Survival Analysis

645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

252
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ocular Surface Toxicity of Antibody-Drug Conjugates: Pathogenesis, Diagnosis, Grading, and Treatment of Ocular Adverse Effects.

Cornea·2026
Same author

Development of a user-informed decision aid for adolescents and young adults' contraceptive care.

JMIR formative research·2026
Same author

Parental Perspectives and Experiences with Genetic Testing and Surveillance for Cancer Predisposition in Healthy Young Children.

The Journal of pediatrics·2026
Same author

Development and pre-testing of a family-centered digital intervention to help families know what to EXPECT from pediatric acute lymphoblastic leukemia therapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Food insecurity, dietary quality, and cardiovascular risk among early childhood cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.

Cancer·2026
Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026
Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026
Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026
Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026
Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.3K

Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer.

Colleen A Kelly1,2,3,4, Morgan A Paul5, Jennifer Kellett1

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Pediatric Blood & Cancer
|October 15, 2025
PubMed
Summary
This summary is machine-generated.

Pediatric RISE, a direct cash support program, proved acceptable and valuable for low-income children with cancer, reducing hardship without impacting government benefits. Refinements are underway to increase support duration and amount.

Keywords:
cash transferhealth disparitiespediatric oncologypovertysocial determinants of health

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.8K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

565

Related Experiment Videos

Last Updated: Jan 15, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.3K
Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

12.8K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

565

Area of Science:

  • Pediatric Oncology
  • Health Equity
  • Socioeconomic Interventions

Background:

  • Poverty is linked to worse outcomes in childhood cancer, yet no financial support interventions exist in pediatric oncology.
  • Direct cash support programs show promise for improving child health outcomes.
  • Pediatric Resource Intervention to Support Equity (RISE) was developed to address financial hardship in pediatric cancer patients.

Purpose of the Study:

  • To pilot and refine the Pediatric RISE intervention, a novel direct cash support program for low-income children with cancer.
  • To assess the acceptability, satisfaction, and barriers to utilization of the Pediatric RISE program.
  • To inform refinements of the Pediatric RISE intervention based on parent feedback and outcomes.

Main Methods:

  • A single-arm pilot study was conducted with low-income children undergoing cancer treatment.
  • Participants received twice-monthly cash disbursements and optional benefits counseling for three months.
  • Parent surveys and qualitative interviews were used to evaluate the intervention's feasibility and impact.

Main Results:

  • Families received all intended cash disbursements, utilizing funds for essential needs and reporting reduced material hardship.
  • The Pediatric RISE intervention was found to be acceptable and useful, with no reported loss of government benefits.
  • Parents indicated a need for larger cash disbursements and longer intervention duration to address treatment-related income loss.

Conclusions:

  • The Pediatric RISE intervention is acceptable and valuable for pediatric cancer patients, effectively mitigating risks to government benefits.
  • Parent feedback guided refinements, including increased disbursement amounts and extended duration.
  • A refined, multi-site randomized trial is currently evaluating the enhanced Pediatric RISE intervention.